Current Report Filing (8-k)
August 22 2017 - 9:24AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d) of The
Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
August 21, 2017
CELGENE
CORPORATION
(Exact name of registrant as specified in
its charter)
Delaware
|
001-34912
|
22-2711928
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
86 Morris Avenue, Summit, New Jersey
|
07901
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant’s telephone number, including
area code: (908) 673-9000
(Former name or former address, if changed
since last report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
¨
|
ITEM 5.02
|
DEPARTURE OF DIRECTORS
OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY
ARRANGEMENTS OF CERTAIN OFFICERS.
|
Celgene Corporation (the “Company”)
announced that, effective August 21, 2017, Michael Pehl retired from the Company as President, Hematology & Oncology. The
Company thanks Michael for his years of service and wishes him well.
Nadim Ahmed will assume the responsibilities
of President, Hematology & Oncology and will report to Scott Smith, the Company’s COO. Before this appointment,
Nadim
was President, Worldwide Markets, Hematology & Oncology since March 2016. Nadim served as General Manager, US Hematology &
Oncology from August 2014 until March 2016.
Nadim joined the Global Marketing team in 2010 as Global Head of Marketing
for our Myeloma Franchise after holding positions of increasing responsibility in Clinical Development, Medical Affairs, Global
and US Marketing at GSK. Nadim holds a Bachelor of Science Degree in Pharmacology from University College London, UK and a Master
of Science Degree in Information Technology from Loughborough University, UK.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
CELGENE CORPORATION
|
|
|
|
|
|
|
|
|
|
Date: August 22, 2017
|
By:
|
/s/Peter N. Kellogg
|
|
|
|
Peter N. Kellogg
|
|
|
|
Executive Vice President
|
|
|
|
Chief Financial Officer
|
|
|
|
(principal financial and accounting officer)
|
|
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Apr 2023 to Apr 2024